Department of Obstetrics and Gynecology, University Medical Center, The University of Arizona, Tucson, AZ (RM Wei, MG Hill).
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA (M Bounthavong).
Am J Obstet Gynecol MFM. 2022 Jul;4(4):100627. doi: 10.1016/j.ajogmf.2022.100627. Epub 2022 Mar 28.
Women with obesity are likely to experience longer lengths of labor and are at an increased risk of cesarean delivery. We hypothesized that high-dose oxytocin would decrease the time to delivery in a cohort of women with obesity undergoing induction of labor.
This study aimed to assess whether women with obesity benefited from higher doses of oxytocin for induction of labor.
A double-blinded randomized controlled trial was conducted to evaluate the effect of low-dose and high-dose oxytocin on length of labor. We recruited women who were undergoing induction of labor at ≥37 weeks of gestation. Patients were randomly assigned in a 1:1 ratio to receive low-dose or high-dose oxytocin stratified by obesity level (obese and lean). The primary outcome was length of time (minutes) to vaginal delivery. The secondary outcomes included overall cesarean delivery rate, cesarean delivery for labor arrest, maximum oxytocin infusion rate, oxytocin infusion discontinuation, oxytocin infusion decrease, blood loss, neonatal intensive care unit admission, and neonatal Apgar scores.
A total of 140 patients were randomized into receiving low-dose and high-dose oxytocin stratified into obese and lean stratum (35 for all strata). The primary outcome, time to vaginal delivery, was similar between the low-dose and high-dose oxytocin groups in the lean stratum (796 [±411] vs 694 [±466] minutes; P=.363) and the stratum with obesity (715 [±497] vs 762 [±594] minutes; P=.733). Kaplan-Meier curves between the low-dose and high-dose oxytocin groups were not significantly different in the lean stratum (P=.391) and the stratum with obesity (P=.692). There were 5 cesarean deliveries (14.29%) in the low-dose oxytocin lean stratum vs 2 cesarean deliveries (5.71%) in the high-dose oxytocin lean stratum (P=.232). There were 4 cesarean deliveries (11.43%) in the low-dose oxytocin stratum with obesity vs 1 cesarean delivery (2.86%) in the high-dose oxytocin stratum with obesity (P=.164). There was no difference in the incidence of postpartum hemorrhage between the lean stratum (P=0.526) and the stratum with obesity (P=0.212). There was no difference in mean estimated blood loss between the lean stratum (P=.472) and the stratum with obesity (P=.215).
There was no difference in time to delivery between the low-dose and high-dose oxytocin protocols in either the lean cohorts or cohorts with obesity undergoing induction of labor. We did observe a trend toward a lower rate of cesarean delivery in both lean women and women with obesity when high-dose oxytocin was used.
肥胖女性可能经历更长的分娩时间,并增加剖宫产的风险。我们假设高剂量催产素会缩短肥胖女性引产的分娩时间。
本研究旨在评估肥胖女性接受催产素引产时是否受益于更高剂量的催产素。
进行了一项双盲随机对照试验,以评估低剂量和高剂量催产素对分娩时间的影响。我们招募了在 37 周以上进行引产的女性。患者按肥胖水平(肥胖和瘦)以 1:1 的比例随机分配接受低剂量或高剂量催产素。主要结局是阴道分娩的时间(分钟)。次要结局包括总剖宫产率、因产程停滞而行剖宫产、最大催产素输注率、催产素输注停止、催产素输注减少、出血量、新生儿重症监护病房入院和新生儿 Apgar 评分。
共有 140 名患者被随机分为低剂量和高剂量催产素组,分为肥胖和瘦组(每组 35 名)。在瘦组(796 [±411] 与 694 [±466] 分钟;P=.363)和肥胖组(715 [±497] 与 762 [±594] 分钟;P=.733)中,低剂量和高剂量催产素组的主要结局,即阴道分娩时间,相似。在瘦组(P=.391)和肥胖组(P=.692)中,低剂量和高剂量催产素组之间的 Kaplan-Meier 曲线没有显著差异。低剂量催产素瘦组有 5 例剖宫产(14.29%),高剂量催产素瘦组有 2 例剖宫产(5.71%)(P=.232)。低剂量催产素肥胖组有 4 例剖宫产(11.43%),高剂量催产素肥胖组有 1 例剖宫产(2.86%)(P=.164)。瘦组(P=0.526)和肥胖组(P=0.212)之间产后出血发生率无差异。瘦组(P=0.472)和肥胖组(P=0.215)之间平均估计出血量无差异。
在接受引产的瘦人群组和肥胖人群组中,低剂量和高剂量催产素方案之间的分娩时间无差异。我们确实观察到在使用高剂量催产素时,肥胖女性和瘦女性的剖宫产率都有降低的趋势。